The report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/508003-dry-atrophic-macular-degeneration-pipeline-review-h1-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews pipeline therapeutics for Dry (Atrophic) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dry (Atrophic) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Dry (Atrophic) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dry (Atrophic) Macular Degeneration
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Dry (Atrophic) Macular Degeneration Overview 11
Therapeutics Development 12
Pipeline Products for Dry (Atrophic) Macular Degeneration – Overview 12
Pipeline Products for Dry (Atrophic) Macular Degeneration – Comparative Analysis 13
Dry (Atrophic) Macular Degeneration – Therapeutics under Development by Companies 14
Dry (Atrophic) Macular Degeneration – Therapeutics under Investigation by Universities/Institutes 16
Dry (Atrophic) Macular Degeneration – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Dry (Atrophic) Macular Degeneration – Products under Development by Companies 21
Dry (Atrophic) Macular Degeneration – Products under Investigation by Universities/Institutes 23
Dry (Atrophic) Macular Degeneration – Companies Involved in Therapeutics Development 24
Aciont Inc. 24
Acucela Inc. 25
Alimera Sciences, Inc. 26
Allergan Plc 27
Apellis Pharmaceuticals, Inc. 28
Astellas Pharma Inc. 29
Benitec Biopharma Limited 30
Biophytis SAS 31
Catalyst Biosciences, Inc. 32
Cell Cure Neurosciences, Ltd. 33
Foamix Pharmaceuticals Ltd. 34
Genentech, Inc. 35
GenSight Biologics S.A. 36
GlaxoSmithKline Plc 37
Icon Bioscience, Inc. 38
Johnson & Johnson 39
Kodiak Sciences, Inc. 40
Access Report @ https://www.wiseguyreports.com/reports/508003-dry-atrophic-macular-degeneration-pipeline-review-h1-2016
Contact Info:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
No comments:
Post a Comment